Introduction: Bioconjugations are swiftly progressing and are being applied to solve
several limitations of conventional Drug Delivery Systems (DDS) such as lack of water solubility,
non-specific, and poor bioavailability. The main goals of DDS are to achieve greater drug effectiveness
and minimize toxicity to the healthy tissues.
Objectives and Methods: In this study, D-glucose was conjugated with eugenol to target the cancer
cells. To identify the implication of the anticancer effect, osteosarcoma (K7M2) cells were cultured
and the anti-proliferative effect was performed using MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide assay] test in order to evaluate the viability and toxicity
on cells with various concentrations of eugenol and D-glucose-eugenol conjugate in 24-hour incubation.
Results: It was found that, the successful confirmation of the conjugation between D-glucose and
eugenol was obtained by 1H NMR spectroscopy. MTT assay showed inhibitory concentration
(IC50 value) of D-glucose-eugenol was at 96.2 μg/ml and the decreased of osteosarcoma cell survival
Conclucion: These findings strongly indicate that K7M2 cells would be affected by toxicity of Dglucose-
eugenol. Therefore, the present study suggests that D-glucose-eugenol has high potential
to act as an anti-proliferative agent who may promise a new modality or approach as the drug delivery
treatment for cancer or chemotherapeutic agent.